ABBV : Analysis & Opinions

  1. Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - ...

    January 28, 2015
    Abbott Laboratories (ABT) is scheduled to report fourth-quarter 2014 results before the opening bell on Jan 29, 2015.
  2. Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst ...

    January 28, 2015
    AbbVie's (ABBV) earnings track record has been good with the company beating expectations consistently in the last three ...
  3. Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst ...

    January 28, 2015
    Novartis' core earnings per share came in at $1.21, up from $1.18 in the year-ago period and beat the Zacks Consensus Estimate ...
  4. Can St. Jude Medical (STJ) Keep Earnings Streak Alive? - Analyst ...

    January 27, 2015
    Our proven model shows that St. Jude Medical Inc. (STJ) is likely to beat earnings because it has the right combination of ...
  5. Will Cardinal Health (CAH) Surprise Earnings This Season? - Analyst ...

    January 27, 2015
    Our proven model does not conclusively show that Cardinal Health, Inc. (CAH) is likely to beat earnings this quarter.
  6. Will PerkinElmer's (PKI) Earnings Disappoint This Season? - Analyst ...

    January 27, 2015
    Our proven model does not conclusively show that PerkinElmer (PKI) is likely to beat earnings this quarter.
  7. Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst ...

    January 27, 2015
    AmerisourceBergen Corporation (ABC) one of the world's largest pharmaceutical services companies with focus on drug distribution ...
  8. Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst ...

    January 27, 2015
    Celgene Corporation is scheduled to report fourth-quarter 2014 results on Jan 29, before the opening bell.
  9. Varian Medical (VAR): Will Earnings Disappoint in Q1? - Analyst ...

    January 27, 2015
    Varian Medical Systems Inc. (VAR) is set to report first-quarter 2015 results on Jan 28.
  10. Will Baxter International (BAX) Disappoint Earnings in Q4? - ...

    January 27, 2015
    Baxter International Inc. (BAX) is set to report fourth-quarter 2014 results on Jan 29.
  11. Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst ...

    January 27, 2015
    Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report its fourth-quarter 2014 results on Jan 29, before the opening ...
  12. Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst ...

    January 27, 2015
    Investor focus will remain on Biogen's (BIIB) oral MS treatment, Tecfidera's, performance.
  13. Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst ...

    January 27, 2015
    Will Vertex (VRTX) post a lower-than-expected loss in Q4 on higher revenues and lower costs?
  14. Can CR Bard (BCR) Keep the Earnings Streak Alive in Q4? - Analyst ...

    January 27, 2015
    We expect CR Bard Inc. (BCR) to beat earnings when the company reports its fourth quarter and full year 2014 financial numbers ...
  15. Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst ...

    January 27, 2015
    Pfizer's (PFE) 2015 guidance disappointed with results expected to be hit by genericization as well as unfavorable currency ...
  16. Will Accuray (ARAY) Disappoint Earnings Estimates in Q2? - Analyst ...

    January 23, 2015
    Accuray Inc. (ARAY) is set to report second-quarter 2015 results on Jan 27.
  17. Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst ...

    January 23, 2015
    The EC has approved Sanofi's (SNY) Cerdelga for the treatment of certain adults suffering from Gaucher disease type I.
  18. Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - ...

    January 23, 2015
    Bristol-Myers Squibb Company (BMY) is scheduled to report its fourth-quarter 2014 results on Jan 27, before the opening bell.
  19. Will Stryker (SYK) Disappoint this Earnings Season? - Analyst ...

    January 23, 2015
    Stryker Corp (SYK) is set to report fourth-quarter 2015 results on Jan 27.
  20. Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst ...

    January 23, 2015
    Will Pfizer's (PFE) earnings streak continue despite the entry of Celebrex generics in late December?
  21. Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, ...

    January 21, 2015
    The hepatitis C virus (HCV) pricing battle is heating up with Gilead (GILD) signing on with quite a few PBMs and health care ...
  22. Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - ...

    January 20, 2015
    Positive news flowed in for Novartis AG (NVS) when the European Commission approved its biologic Cosentyx (secukinumab) for ...
  23. Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst ...

    January 20, 2015
    Sanofi (SNY) announced that it has entered into a strategic agreement with Boehringer Ingelheim
  24. Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst ...

    January 20, 2015
    Novo Nordisk A/S (NVO) announced that the company will first launch its combination diabetes drug, Xultophy, in Switzerland.
  25. J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst ...

    January 20, 2015
    J&J's fourth quarter results were mixed with the company beating on earnings and missing on revenues.
  26. Will Intuitive Surgical (ISRG) Disappoint Earnings in Q4? - Analyst ...

    January 20, 2015
    Intuitive Surgical Inc. (ISRG) is set to report fourth-quarter 2014 results on Jan 22.
  27. Will Quality Systems (QSII) Surprise Earnings this Quarter? - ...

    January 20, 2015
    Quality Systems Inc. (QSII) is set to report third-quarter 2015 results on Jan 22
  28. AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst ...

    January 19, 2015
    Approval was expected as the CHMP had provided a positive opinion late last year.
  29. Roche to Acquire French Biotechnology Company Trophos - Analyst ...

    January 19, 2015
    Roche (RHHBY) announced today that will acquire privately-held French biotechnology company Trophos.
  30. Celgene Up as Otezla Gains EU Approval for Two Indications - ...

    January 19, 2015
    Celgene Corporation announced that the European Commission has granted approval to Otezla for two therapeutic indications.
  31. Will Pharmaceutical Segment Drive J&J Q4 Earnings Again? - Analyst ...

    January 19, 2015
    Will pharma product sales and newly launched products continue to be the driving force in the fourth quarter?
  32. Will Logitech (LOGI) Keep the Earnings Streak Alive in Q3? - ...

    January 19, 2015
    Logitech International SA (LOGI) is set to report third-quarter 2014 results on Jan 22.
  33. Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst ...

    January 13, 2015
    The Nutritionals unit at Perrigo Company (PRGO) has inked a five-year supply agreement with Ferrara Candy Company.
  34. Shire to Acquire NPS Pharmaceuticals for $5.2B - Analyst Blog

    January 12, 2015
    In a move to further strengthen its rare disease portfolio, Shire plc (SHPG) announced that it will acquire NPS Pharmaceuticals, ...
  35. Novartis Submits NDA for Ultibro & Seebri Breezhaler - Analyst ...

    January 12, 2015
    Novartis (NVS) recently announced positive top-line results from phase III trials on chronic obstructive pulmonary disease ...
  36. Myriad's Tumor-Based Cancer Test Wins CE Mark, Shares Up - Analyst ...

    January 12, 2015
    Myriad Genetic's (MYGN) Tumor BracAnalysis CDx has become the first ever tumor-based companion diagnostic test to receive ...
  37. Infinity Pharmaceuticals Falls on Duvelisib Study Results - Analyst ...

    January 9, 2015
    Infinity Pharmaceuticals' (INFI) duvelisib failed to meet the primary endpoint in a phase II study conducted in moderate-to-severe ...
  38. AbbVie 2015 Earnings Guidance Projects Strong Y/Y Growth - Analyst ...

    January 9, 2015
    AbbVie (ABBV) announced that it expects earnings in the range of $4.25 to $4.45 per share for 2015.
  39. Arena Pharmaceuticals Soars on Positive Study Results - Analyst ...

    January 8, 2015
    Arena Pharmaceuticals' (ARNA) shares skyrocketed after announcing encouraging results from a phase Ib study on APD334.
  40. Novartis' Biosimilar of Neupogen Gets Favorable Opinion - Analyst ...

    January 8, 2015
    Novartis' (NVS) generic arm, Sandoz, announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory ...
  41. Pfizer Boosts Vaccine Pipeline with Redvax Acquisition - Analyst ...

    January 7, 2015
    Pfizer's (PFE) acquisition of Redvax makes the company one of the leaders in CMV research and development.
  42. Gilead to Purchase Liver Disease Program from Phenex - Analyst ...

    January 7, 2015
    Gilead Sciences, Inc. announced that it has entered into an agreement with Phenex Pharmaceuticals.
  43. Roche Collaborates with 23andMe for Parkinson's Disease - Analyst ...

    January 7, 2015
    Roche (RHHBY) and personal genetics company 23andMe, Inc. announced an agreement to make breakthroughs in therapeutic research ...
  44. Pharmacyclics Reports Encouraging Data on Cancer Drug - Analyst ...

    January 6, 2015
    Pharmacyclics, Inc. (PCYC) announced encouraging data on its oncology drug, Imbruvica.
  45. Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly ...

    January 2, 2015
    Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company ...
  46. AbbVie Inc. (ABBV): New Analyst Report from Zacks Equity Research ...

    January 2, 2015
    AbbVie's third quarter EPS of $0.89, up 8.5% y-o-y,, surpassed the Zacks Consensus Estimate of $0.78. Revenues grew 7.8% ...
  47. Bull of the Day: Incyte (INCY) - Bull of the Day

    January 1, 2015
    Bull of the Day: Incyte (INCY) - Bull of the Day
  48. NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst ...

    December 31, 2014
    NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ...
  49. Repros Gains on Positive Updates on the Status of Androxal - ...

    December 30, 2014
    Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission ...
  50. Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst ...

    December 30, 2014
    Roche (RHHBY) announced that the FDA has granted Emergency Use Authorization for the LightMix Ebola Zaire rRT-PCR Test.
  51. 3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog

    December 30, 2014
    Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
  52. Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis ...

    December 29, 2014
    Novartis (NVS) announced that the Japanese Ministry of Health, Labour and Welfare has approved Cosentyx (secukinumab) for ...
  53. Novartis' Alcon's Travatan Obtains Label Expansion in the EU ...

    December 26, 2014
    Novartis AG (NVS) recently announced that its ophthalmology arm Alcon was granted a label expansion by the European Commission ...
  54. Roche' (RHHBY) Blood Cancer Drug Gazyva's Label Updated - Analyst ...

    December 26, 2014
    Roche (RHHBY) announced that the FDA has approved a supplemental biologics license application (sBLA) for its blood cancer ...
  55. After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst ...

    December 26, 2014
    Gilead Sciences Inc. has plunged approximately 15.8% after pharmacy benefit manager Express Scripts entered into an agreement ...
  56. Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen ...

    December 24, 2014
    Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) ...
  57. Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst ...

    December 23, 2014
    Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include ...
  58. Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs ...

    December 23, 2014
    Gilead shares fell more than 10 percent in Monday trading following news that AbbVie and Express Scripts signed an exclusive ...
  59. AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst ...

    December 22, 2014
    The FDA has cleared AstraZeneca's (AZN) Lynparza as a monotherapy for the maintenance treatment of adults suffering from ...
  60. AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst ...

    December 22, 2014
    AbbVie's (ABBV) Viekira Pak will be entering the HCV market which is currently dominated by Gilead.
  61. Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst ...

    December 22, 2014
    Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
  62. Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst ...

    December 22, 2014
    Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded ...
  63. Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst ...

    December 19, 2014
    Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, ...
  64. AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst ...

    December 19, 2014
    AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian ...
  65. NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst ...

    December 18, 2014
    A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
  66. Novartis Successfully Expands Signifor Label in the U.S. - Analyst ...

    December 17, 2014
    Novartis's (NVS) Signifor long-acting release was approved in the U.S. for the acromegaly indication.
  67. Will MedTech Gain from Republican Promises? - Industry Outlook

    December 4, 2014
    Will MedTech Gain from Republican Promises? - Industry Outlook
  68. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  69. A Multi-Asset Income ETF For Defensive Investors

    November 14, 2014
    In light of market volatility and worries that stocks are overbought, one product worth noting is the Guggenheim Multi-Asset ...
  70. Global Tensions and Fear - Ahead of Wall Street

    September 23, 2014
    The start of an expanded air campaign in the Iraq-Syria theater and weak data out of Europe provide the unsettling backdrop ...
  71. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  72. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  73. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  74. MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook

    May 1, 2014
    MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
  75. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  76. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  77. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  78. Biotechnology: Some of the Strongest Stocks on Nearly Any Time ...

    September 18, 2013
    Biotechnology is an industry which as has lead the very strong healthcare sector on almost every time frame over the last ...
  79. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  80. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  81. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  82. Warning: The Rebound May Be Over For Big Pharma

    June 10, 2013
    As investors were picking up the pieces after the dot-com implosion, they came across another troubled sector. A series ...
  83. Strategy for Trading High Flying Healthcare Stocks

    April 17, 2013
    Over the past week, month and three months, the healthcare sector has been the top performer.
  84. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
  85. Abbott Spins Off Pharma Business - Analyst Blog

    January 3, 2013
    Abbott Laboratories (ABT) recently announced that the company has separated its research-based pharmaceuticals business by ...
Trading Center